Blood test study for HR+ breast cancer treatment monitoring
Part of Cancer, Skin clinical trials.
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone receptor-positive (HR+) breast cancer that has spread to other parts of the body (metastatic).
- You are either about to start, or are already receiving, a standard treatment for your breast cancer (such as a CDK4/6 inhibitor with endocrine therapy, or endocrine therapy alone).
- You are not currently taking any experimental (investigational) drugs.
- You do not have early-stage breast cancer, and you are not a male.
- You do not have another active cancer (except for some skin cancers or early cervical cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
This study uses a lab “biomarker” test to help doctors choose the best first treatment for people with HR+ (hormone-receptor positive), HER2-negative metastatic or unresectable breast cancer. The goal is to see if this biomarker-guided approach can improve which therapy you start with.
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.